Back from the future: treating hepatitis C virus with conventional interferon.
作者信息
Puri Pankaj, Saraswat Vivek A
机构信息
Department of Gastroenterology, Command Hospital (SC), Pune, India.
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
出版信息
J Clin Exp Hepatol. 2012 Mar;2(1):3-6. doi: 10.1016/S0973-6883(12)60076-0. Epub 2012 Apr 12.
Abstract
摘要
相似文献
1
Back from the future: treating hepatitis C virus with conventional interferon.从未来回归：用传统干扰素治疗丙型肝炎病毒
J Clin Exp Hepatol. 2012 Mar;2(1):3-6. doi: 10.1016/S0973-6883(12)60076-0. Epub 2012 Apr 12.
2
Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.印度丙型肝炎病毒所致慢性肝炎（CH-C）的治疗：一项比较每日干扰素-α-2b与利巴韦林联用和每日干扰素-α-2b与甘草酸联用的随机对照多中心研究。
J Clin Exp Hepatol. 2012 Mar;2(1):10-8. doi: 10.1016/S0973-6883(12)60079-6. Epub 2012 Apr 12.
3
Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.个体化给药疗效与固定剂量给药对比以评估聚乙二醇化干扰素最佳治疗方案（IDEAL）试验的科学依据和研究设计：确定基因1型慢性丙型肝炎患者的最佳给药剂量
J Viral Hepat. 2008 Jul;15(7):475-81. doi: 10.1111/j.1365-2893.2008.00973.x. Epub 2008 Mar 24.
4
5
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.聚乙二醇化干扰素α-2a和α-2b联合利巴韦林治疗慢性丙型肝炎：系统评价与经济学评估
Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390.
6
Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.印度北部一家三级医疗中心对慢性丙型肝炎患者应用聚乙二醇化干扰素α-2b和利巴韦林治疗的临床特征及反应的重新评估
J Clin Exp Hepatol. 2014 Jun;4(2):101-5. doi: 10.1016/j.jceh.2014.05.012. Epub 2014 Jun 18.
7
Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.聚乙二醇干扰素 α-2b 联合利巴韦林治疗基因型 1 和 4 慢性丙型肝炎患者的前瞻性、随机、多中心、开放性研究。
Clin Gastroenterol Hepatol. 2010 Jan;8(1):66-71.e1. doi: 10.1016/j.cgh.2009.08.036. Epub 2009 Sep 10.
8
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.甲硫米泊苷、聚乙二醇干扰素和利巴韦林用于1型慢性丙型肝炎中对聚乙二醇干扰素和利巴韦林无反应者的治疗。
Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204.
9
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.聚乙二醇干扰素α-2b联合利巴韦林与聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的成本效益分析
J Manag Care Pharm. 2005 Oct;11(8):687-94. doi: 10.18553/jmcp.2005.11.8.687.
10
[Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].[聚乙二醇化干扰素α-2b用于慢性丙型肝炎双重（聚乙二醇化干扰素α-2b和利巴韦林）及三重（西米普明、聚乙二醇化干扰素α-2b和利巴韦林）抗病毒治疗方案的可能性。临床试验及日常临床实践经验综述]
Ter Arkh. 2016;88(11):156-162. doi: 10.17116/terarkh20168811156-162.
本文引用的文献
1
Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.印度丙型肝炎病毒所致慢性肝炎（CH-C）的治疗：一项比较每日干扰素-α-2b与利巴韦林联用和每日干扰素-α-2b与甘草酸联用的随机对照多中心研究。
J Clin Exp Hepatol. 2012 Mar;2(1):10-8. doi: 10.1016/S0973-6883(12)60079-6. Epub 2012 Apr 12.
2
Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.白细胞介素28B基因多态性与丙型肝炎——将关联转化为临床决策
J Clin Exp Hepatol. 2011 Jun;1(1):27-33. doi: 10.1016/S0973-6883(11)60115-1. Epub 2011 Aug 26.
3
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.治疗基因型 3 慢性丙型肝炎患者——现有和未来的治疗方法。
Liver Int. 2012 Feb;32 Suppl 1:141-5. doi: 10.1111/j.1478-3231.2011.02715.x.
4
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.丙型肝炎病毒基因型 3 与持续病毒 C 肝硬化患者肝细胞癌发病率升高有关。
J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.
5
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.1型慢性丙型肝炎病毒感染治疗的最新进展：美国肝病研究协会2011年实践指南
Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
6
Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.预测聚乙二醇干扰素α与利巴韦林联合治疗基因 3 型慢性丙型肝炎患者的持续病毒学应答。
Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3. Epub 2011 Jun 25.
7
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.特拉匹韦单药或与聚乙二醇干扰素和利巴韦林联合治疗可降低慢性基因型 2 但不能降低基因型 3 感染患者的 HCV RNA。
Gastroenterology. 2011 Sep;141(3):881-889.e1. doi: 10.1053/j.gastro.2011.05.046. Epub 2011 May 31.
8
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.亚洲、澳大利亚和埃及丙型肝炎病毒流行病学的系统评价。
Liver Int. 2011 Jul;31 Suppl 2:61-80. doi: 10.1111/j.1478-3231.2011.02540.x.
9
A new standard of care for the treatment of chronic HCV infection.慢性 HCV 感染治疗的新标准。
Nat Rev Gastroenterol Hepatol. 2011 May;8(5):257-64. doi: 10.1038/nrgastro.2011.49. Epub 2011 Apr 5.
10
'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?“易于治疗”的基因型并不平等：快速病毒学应答 (RVR) 能否拉平起跑线？
J Hepatol. 2011 Aug;55(2):466-73. doi: 10.1016/j.jhep.2011.02.004. Epub 2011 Feb 18.
Zotero 插件